타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Dupixent (dupilumab) | Ebglyss (lebrikizumab-lbkz) | Triamcinolone | Mycophenolate |
Overview Company | Sanofi / Regeneron | Eli Lilly | Novartis | Novartis |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-4Rα | IL-13 | Diabetic Macular Edema | Rheumatic Disease |
Overview Indication | Atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis | Moderate-to-severe atopic dermatitis | Psoriasis; Atopic Dermatitis | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | ACTIVE | RECRUITING |
Overview Content status | Curated Core | Curated Core | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | Approved (flag incomplete) | Approved (flag incomplete) |
Positioning Key differentiator | Novel targets under investigation include MRGPRs, PARs, KIT receptors, OX-40, and sodium channels | unique disposition of simvastatin rather than enzyme or transporter inhibition | — | — |
Positioning Known limitation | Non-Type 2 inflammation and inadequate trough levels. | Concurrent IL-4 signaling and non-Type 2 dermatitis. | — | — |
MoA Mechanism | Dupilumab binds IL-4Rα subunit shared by IL-4 type I and IL-13 type II receptors, inhibiting IL-4 and IL-13 signaling, reducing Type 2 inflammation (IgE, eosinophils, Th2 cytokines). | Lebrikizumab binds IL-13 with high affinity, blocking IL-13Rα1/IL-4Rα signaling and downstream Type 2 inflammation in skin (barrier dysfunction, pruritus, eosinophilia). | targeting of STING-TBK1 signaling | — |
MoA Biomarker | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu | EASI, IGA 0/1, pruritus NRS. | biomarkers have shown that both TA and DEX implant are effective in promoting scattered punctate and plaque-l | biomarkers and therapeutic targets |
Toxicology Species | Mouse | Cynomolgus monkey | — | — |
Toxicology Major finding | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | Conjunctivitis, nasopharyngitis, injection-site reactions; herpes zoster warnings per class. | — | — |
Toxicology CRS | N/A | N/A | — | — |
Clinical Safety signal | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | Conjunctivitis, nasopharyngitis, injection-site reactions; herpes zoster warnings per class. | — | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 4개 · 임상 갱신 필요 4개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ||||
|---|---|---|---|---|
Overview Program | Dupixent (dupilumab) | Ebglyss (lebrikizumab-lbkz) | Triamcinolone | Mycophenolate |
Overview Company | Sanofi / Regeneron | Eli Lilly | Novartis | Novartis |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | IL-4Rα | IL-13 | Diabetic Macular Edema | Rheumatic Disease |
Overview Indication | Atopic dermatitis, asthma, CRSwNP, EoE, prurigo nodularis | Moderate-to-severe atopic dermatitis | Psoriasis; Atopic Dermatitis | Psoriasis; Atopic Dermatitis |
Overview Phase | APPROVED | APPROVED | APPROVED | APPROVED |
Overview Status | APPROVED | APPROVED | ACTIVE | RECRUITING |
Overview Content status | Curated Core | Curated Core | Limited Data | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · Curated Core | Editorial scope · limited data | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Established | Development Signal · Established | Development Signal · Established |
Overview Approval status | FDA approved | FDA approved | Approved (flag incomplete) | Approved (flag incomplete) |
Positioning Key differentiator | Novel targets under investigation include MRGPRs, PARs, KIT receptors, OX-40, and sodium channels | unique disposition of simvastatin rather than enzyme or transporter inhibition | — | — |
Positioning Known limitation | Non-Type 2 inflammation and inadequate trough levels. | Concurrent IL-4 signaling and non-Type 2 dermatitis. | — | — |
MoA Mechanism | Dupilumab binds IL-4Rα subunit shared by IL-4 type I and IL-13 type II receptors, inhibiting IL-4 and IL-13 signaling, reducing Type 2 inflammation (IgE, eosinophils, Th2 cytokines). | Lebrikizumab binds IL-13 with high affinity, blocking IL-13Rα1/IL-4Rα signaling and downstream Type 2 inflammation in skin (barrier dysfunction, pruritus, eosinophilia). | targeting of STING-TBK1 signaling | — |
MoA Biomarker | biomarkers and clinical characteristics and highlight the need for standardized, methodologically rigorous fu | EASI, IGA 0/1, pruritus NRS. | biomarkers have shown that both TA and DEX implant are effective in promoting scattered punctate and plaque-l | biomarkers and therapeutic targets |
Toxicology Species | Mouse | Cynomolgus monkey | — | — |
Toxicology Major finding | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | Conjunctivitis, nasopharyngitis, injection-site reactions; herpes zoster warnings per class. | — | — |
Toxicology CRS | N/A | N/A | — | — |
Clinical Safety signal | Conjunctivitis, injection-site reactions, eosinophilia; herpes zoster caution. | Conjunctivitis, nasopharyngitis, injection-site reactions; herpes zoster warnings per class. | — | — |
Clinical Program phase | APPROVED | APPROVED | APPROVED | APPROVED |
Clinical Trial activity | No active/completed counts | No active/completed counts | No active/completed counts | No active/completed counts |
추천 비교
추천 비교